1. Introduction {#sec1}
===============

Reconstruction of critical-sized bone defects is a challenging procedure for orthopedic surgeon. Various procedures have been introduced for bone defect treatment in clinic for example, autologous bone grafts, allogeneous bone grafts, and xenogeneous bone grafts, but the clinical outcomes are varied and lead to donor site morbidities ([@bib81]; [@bib85]). Osteoconductive biomaterials are also available in clinical treatment. However, a therapeutic outcome of bone repair and regeneration in large defects or in compromised host is still unsatisfied. Hence, bone tissue engineering has been proposed as a promising tool for correcting simple and complicated bone defects ([@bib14]). Studies supporting the potential application of mesenchymal stem cell (MSC)-based bone tissue engineering employing *in vitro* and laboratory animal models have been reported ([@bib67]). However, most of the evidences are focused on human application. In this review, fundamental principles and potential applications of MSC-based bone tissue engineering for veterinary practice are summarized. In addition, the canine models exhibited many features which are valuable as model manners for further human application ([@bib64]). Animal models for bone tissue engineering have involved in various bone defect and bone disease models which are able to accelerate the translation of knowledge to clinical practice in both human and veterinary applications ([@bib57]).

2. Bone tissue engineering {#sec2}
==========================

Tissue engineering is a multidisciplinary study founded on the basis of cell biology, developmental biology, bioengineering, and biomaterial science. Tissue engineering approach aims to develop the biological substitutes that restore, maintain, or improve function of target tissues or organs ([@bib11]; [@bib17]; [@bib46]). Conventionally, three main components are comprised of matrix (scaffolds), applied cues (biochemical or biophysical cues), and cell resources which are required for an establishment of successful tissue engineering ([@bib11]; [@bib17]).

3. Scaffolds in bone tissue engineering {#sec3}
=======================================

Scaffolds are functioned as the supportive extracellular matrix (ECM). Scaffolds should support cell adherence, spreading, proliferation, differentiation, maturation, communication, and ECM production ([@bib17]). Scaffolds in bone tissue engineering are usually osteoconductive materials which provide an environment for bone formation *in vivo*. However, osteoinductive materials are also utilized as bone tissue engineering scaffolds since they could promote osteogenic differentiation leading to bone regeneration ([@bib10]; [@bib15]; [@bib31]).

3.1. Biomaterials for bone scaffolds {#sec3.1}
------------------------------------

Different materials exhibit specific advantages and disadvantages for bone scaffold utilization. In this regard, natural polymers demonstrate high biocompatibility and contain biological activity. However, low mechanical strength and fabrication limitation are main disadvantages. Synthetic materials like ceramics with calcium phosphate-based materials exhibit osteoinductive abilities ([@bib10]). Calcium and phosphate ions have been shown to induce osteogenic differentiation in various cell types ([@bib2]; [@bib4]). Though, some bioceramic materials have a slow degradation rate, resulting in the remaining of materials in newly regenerated bone tissues ([@bib82]). Due to flexible mechanical properties, ease for fabrication, and relatively low cost, biodegradable synthetic polymers have been used as a material of choices for bone tissue engineering scaffolds. However, these materials are lack of bioactivities and some materials are toxic upon degradation ([@bib65]).

To overcome some limitations of specific materials, advanced hybrid biomaterials have been developed. For example, poly(lactic-co-glycolic acid) (PLGA) and PLGA-polycaprolactone (PCL) co-polymer are developed to achieve a designed degradation time ([@bib92]). PLGA-polyphosphazenes polymer blends are generated to prevent biological incompatibility of the degradation products ([@bib23]; [@bib43]). Further, polymer-bioceramic composite materials are initiated to improve osteoinductive properties of polymer materials and to control degradation ability of bioceramics. The exemplification of these polymer-bioceramic composite materials is HA-poly (lactic acid) (PLA), HA-PLGA, HA-gelatin, HA-Chitosan, HA-collagen ([@bib18]; [@bib39]; [@bib40]; [@bib72]; [@bib96]; [@bib100]).

3.2. Scaffold characters for bone regeneration {#sec3.2}
----------------------------------------------

Physical scaffolds' characters have been shown to participate in the osteoinductive and osteoconductive properties. The examples of those physical parameters are porosity, pore size, surface topography, surface roughness, and surface chemical composition. It has been proposed that these physical parameters could directly interact with cells and also indirectly control cells by the absorbed protein on the surface ([@bib68]). Scaffolds with suitable microporosity (i.e. pore size, volume, and interconnectivity) support cell proliferation and migration, nutrient and oxygen flow, vascularization, and ECM production ([@bib51]; [@bib98]). It has been shown that scaffolds with mean pore size \>300 μm could efficiently enhance osteoblast proliferation and differentiation throughout the scaffold due to the thorough delivery of oxygen and nutrient within the scaffold ([@bib32]; [@bib44]; [@bib90]; [@bib93]). However, scaffolds with small pore size (\<200 μm) could only illustrate peripheral osteoblast survival and bone formation ([@bib36]). Nano-scale topography of scaffold plays a crucial role in osteoinduction, osteoconduction, and osseointegration ([@bib69]; [@bib95]). In this regard, it has been shown that rough surface promotes human osteoblast-like cell spreading and proliferation ([@bib61]). Surface chemistry has been shown to participate to cell response. Phosphoric acid treated titanium surface demonstrates similar surface roughness parameters, but a high phosphate and oxygen content is observed on the surface ([@bib63]). Results demonstrate that phosphoric acid treated surface promotes cell attachment and cytoskeletal orientation in murine pre-osteoblast cells ([@bib63]). Taken all evidences together, physical characteristics of scaffolds exhibit a crucial role in biological responses.

3.3. Fabrication and scaffolding techniques {#sec3.3}
-------------------------------------------

As scaffold architecture is an important factor to regulate cell responses. Thus, various technologies are introduced in order to tightly control the fabrication of scaffolds' architecture favoring bone formation. Variety of fabrication techniques have been employed for the production of nano-featured scaffolds i.e. electrospinning ([@bib47]; [@bib91]), molecular self-assembly ([@bib55]; [@bib56]), fiber bonding ([@bib91]), and phase separation ([@bib50]). With computer-based technology, computer assisted design ([@bib17]) computer assisted technology ([@bib14]) systems have been utilized for the production of personalized and anatomical-shaped scaffolds to achieve the complex architecture bone tissues ([@bib30]).

The additional aspect for designing the scaffold is the orthopedic tissue interface (hard tissue-soft tissue interface) which is very important for graft stability and bone regeneration process ([@bib53]). Bone-soft tissue (ligament, tendon, and cartilage) interface is such a complex and multifactorial organization of distinct tissue types required for musculoskeletal homeostasis and physiological functions ([@bib53]; [@bib70]). Designing of layered scaffolds mimicking natural structure and molecular components of bone-soft tissue interface is introduced. It has been reported that three-phase biomaterials composing of ligament-fibrocartilage-bone-like matrixes can support the maintenance of three cell types (fibroblasts, chondrocytes, and osteoblasts) *in vitro* ([@bib86], [@bib87]). In term of bone-cartilage interface, osteochondral interface is a key component organizing load bearing and force distribution ([@bib53]). Various material-forming techniques have been reported for the production of osteochondral interface-mimicking biomaterials including biphasic scaffolds fabricated with polyglycolic acid (PGA) mesh and PLGA/polyethylene glycol foam ([@bib78]), hyaluronan sponge and porous calcium phosphate scaffold ([@bib28]), and photo-polymerized polyethylene glycol-diacrylate hydrogel ([@bib1]). One side of these layered materials is seeded with osteoblasts and another side is seeded with chondrocytes. This co-culture of two cell types on layered materials could simulate the bone-cartilage interface *in vitro.*

To further enhance the bone regenerative capacity of scaffolds, the ability to induce cell homing has been proposed as another key factor. In this regard, cell homing induction could be achieved by two approaches, scaffold-based and/or cell-based strategies ([@bib84]). Scaffolds can be engineered to be more attractive for the cells, leading to the effective angiogenesis and subsequently bone regeneration. The integration of these strategies has been illustrated in the customized cytokine microdelivery system that was incorporated with PCL-based scaffold ([@bib79]). The system could sequentially deliver vascular endothelial growth factor (VEGF), stromal cell-derived factor (SDF)-1, and bone morphogenetic protein (BMP)-6 resulting in the enhanced angiogenesis, MSCs migration, and matrix mineralization, respectively ([@bib79]). Moreover, constructing a bio-adhesive surface on scaffold by immobilizing short protein motifs (e.g. arginine-glycine-aspartic acid (RGD motif) or glycine-phenylalanine-hydroxyproline-glycine-glutamate-arginine (GFOGER) shows the significant effects on cell adhesion, proliferation, and osteogenic differentiation ([@bib29]).

4. MSC-based bone tissue engineering for veterinary practice {#sec4}
============================================================

Applying of appropriate cell resources is necessary for enhancing bone regeneration and neovascularization ([@bib3]). Many studies suggest the use of pluripotent and multipotent stem cells as cell sources to enhance bone regeneration. In this regard, pluripotent stem cells (such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) possess a high differentiation potency and are able to differentiate toward osteogenic lineage upon an appropriate stimulation ([@bib5]; [@bib16]; [@bib37]; C. [@bib99]). However, there are some concerns according to their tumorigenicity and immunological incompatibility after transplanted ([@bib3]). Hence, the application of mesenchymal stem cells (MSCs) has been investigated for bone tissue engineering utilization ([@bib3]). Isolations of MSCs from various tissue resources have been reported for example bone marrow ([@bib13]; [@bib54]), adipose tissues ([@bib101]), dental tissues ([@bib58]; [@bib83]), umbilical cord blood ([@bib73]), peripheral blood ([@bib45]), amniotic fluid ([@bib33]), brain ([@bib20]; [@bib52]), skin ([@bib34]), heart ([@bib22]), kidney ([@bib48], [@bib49]), and liver ([@bib27]). In this review, potential application of three main MSCs in veterinary bone tissue engineering namely a) bone marrow-derived MSCs (BM-MSCs), b) adipose-derived MSCs (AD-MSCs), and c) dental tissue-derived MSCs, is discussed.

Stemness and surface marker expression along with osteogenic gene marker expression upon an *in vitro* induction by these three canine mesenchymal stem cells were summarized in [Table 1](#tbl1){ref-type="table"} and [Table 2](#tbl2){ref-type="table"}, respectively.Table 1Stemness and surface marker expression of canine mesenchymal stem cells.Table 1cBM-MSCscDPSCscAD-SCsSTRO-1− ([@bib12])+ ([@bib24])− ([@bib12])Nanog+ ([@bib12])+ ([@bib24])+ ([@bib12])OCT4+ ([@bib12])N/D+ ([@bib12])Sox2+ ([@bib12])N/D+ ([@bib12])CD8+ ([@bib74])N/D+ ([@bib74])CD4+ ([@bib74])N/D+ ([@bib74])CD9+ ([@bib12])N/D+ ([@bib12])CD11bN/DN/D− ([@bib8])CD14+ ([@bib74])N/D+ ([@bib74])CD29+ ([@bib74])N/D+ ([@bib74])CD34− ([@bib12])N/D− ([@bib12])CD44+ ([@bib12])+ ([@bib38])+ ([@bib8])CD45− ([@bib74])− ([@bib24])− ([@bib8])CD73+ ([@bib74])+ ([@bib24])+ ([@bib74])CD90+ ([@bib12])+ ([@bib24])+ ([@bib8])CD105+ ([@bib12])− ([@bib24])+ ([@bib12])CD146N/D+ ([@bib24])N/D[^1]Table 2Osteogenic gene marker expression by canine mesenchymal stem cells upon an *in vitro* induction.Table 2cBM-MSCscDPSCscAD-SCs*Runx2*Upregulation ([@bib74])N/DUpregulation ([@bib74])*Osteocalcin*Upregulation ([@bib19])N/DUpregulation ([@bib71])*Collagen 1A1*Upregulation ([@bib19])Upregulation ([@bib38])Upregulation ([@bib19])*Osterix*Upregulation ([@bib42])N/DUpregulation ([@bib42])*Osteopontin*Upregulation ([@bib74])Upregulation ([@bib38])Upregulation ([@bib74])*ALP*Upregulation ([@bib42])N/DUpregulation ([@bib74])[^2]

4.1. Bone marrow-derived mesenchymal stem cells (BM-MSCs) {#sec4.1}
---------------------------------------------------------

Human and mouse BM-MSCs have been isolated and well characterized. Human BM-MSCs have been identified as CD10+, CD13+, CD29+, CD44+, CD59+, CD71+, CD73+, CD90 (Thy1)+, CD105+, CD106 (VCAM)+, CD146+, CD166 (ALCAM)+, STRO-1+, CD11a-, CD14-, CD19-, CD31 (PECAM)-, CD34 (C-18)-, CD45-, CD48-, CD135-, and HLA-DR- ([@bib7]; [@bib54]; [@bib66]). Canine BM-MSCs (cBM-MSCs) have been recently isolated and described as the clonogenic cells containing self-renewing and multilineage differentiation capacities. cBM-MSCs are able to differentiate toward osteogenic, chondrogenic, and adipogenic lineages ([@bib19]; [@bib75]; [@bib80]; [@bib88]). These cells express pluripotent stem cell markers, *zinc finger protein 42 (ZFN42 or Rex1)* and *POU class 5 homeobox 1 (Pou5f1)/octamer-binding transcription factor 4 (Oct4)* ([@bib75]). Immunophenotyping characterization by flow cytometry demonstrates that cBM-MSCs express CD44+ and CD90 + but lack of CD14-, CD29-, CD34-, and MHC II- ([@bib80]). Additional analysis of cell surface markers by real-time reverse transcription-polymerase chain reaction (qRT-PCR) revealed that cBM-MSCs were negative for *CD45* and positive for *CD14, CD29, CD44, CD73, CD90, CD105,* and *MHC II* ([@bib80]). PCR array has been used to analyze the pattern of gene expression in cBM-MSCs comparing with peripheral blood mononuclear cells (PBMCs), and the results suggested the set of upregulated genes *(matrix metallopeptidase 2; Mmp2,* and *platelet-derived growth factor receptor β; Pdgfrβ*) and down regulated genes (*protein tyrosine phosphatase receptor type C; Ptprc or Cd45, tumor necrosis factor; Tnf, integrin subunit alpha X; Itgax, beta-2-microglobulin; β2m, interleukin 10; Il10, peroxisome proliferator activated receptor gamma; Pparɣ, transforming growth factor beta 1; Tgfβ1)*, indicating the mesenchymal specific lineage characterization of cBM-MSCs compared with PBMCs ([@bib80]).

*In vitro* and *in vivo* osteogenic differentiation potential of cBM-MSCs has been illustrated ([@bib6]; [@bib19]; [@bib75]; [@bib80]). An *in vitro* osteogenic induction is performed by employing the culture medium containing 40 μg/mL to 50 mg/mL ascorbic acid, 20 nM--100 nM dexamethasone, and 10 μM to 10 mM β-glycerophosphate. The induction period is also varied from 7 to 21 days ([@bib12]; [@bib19]; [@bib75]; [@bib80]; [@bib88]). At the end of the induction period, cells were positively stained with Alizarin Red S or *Von Kossa* silver staining. The upregulation of osteogenic gene markers (*core-binding factor alpha 1 (Cbfa1)/Runt-related transcription factor 2 (Runx2), bone gamma-carboxyglutamic acid-containing protein (Bglap)/osteocalcin (Ocn), collagen type 1 alpha 1 (Col1A1), osterix (Osx),* and *bone sialoprotein I (Bsp-1)/osteopontin (Opn)*) along with the increase of alkaline phosphatase activity are illustrated ([@bib12]; [@bib75]; [@bib80]; [@bib88]). These evidences imply the osteogenic differentiation ability of cBM-MSCs.

Various factors are shown to influence the osteogenic differentiation ability of cBM-MSCs *in vitro.* In this respect, β-glycerophosphate is a source of inorganic phosphate for mineralization *in vitro.* It is cleaved by alkaline phosphatase enzyme resulting in the release of phosphate ions. Increasing of β-glycerophosphate concentration to 20 and 40 mM enhances an upregulation of *Osx* and *Col1A1* mRNA expression without significant effects on alkaline phosphatase activity and mineral deposition ability compared with 10 mM β-glycerophosphate supplementation ([@bib75]). Supplementation of recombinant human bone morphogenic protein-2 (rhBMP-2) in osteogenic inductive medium increases an *in vitro* alkaline phosphatase activity and mineralization in dose-dependent manner ([@bib12]).

Potential application of cBM-MSCs in bone tissue engineering has been studied in various canine bone defect models. Segmental long bone defects treated with cBM-MSCs loaded HA-tricalcium phosphate has been reported ([@bib6]). Results show that callus formation is observed throughout the length of the defect at eight weeks after transplantation ([@bib6]). New bone formation entire the implant was found at sixteen weeks post-transplant ([@bib6]). Further, transplantation of cBM-MSCs in canine mandibular segmental bone defect has been investigated ([@bib97]). In this regard, osteogenically induced autologous cBM-MSCs seeded on biodegradable β-tricalcium phosphate (β-TCP) scaffold could regenerate the mandibular defects compared with the control ([@bib97]). At 32 weeks post-operation, the completed bone union of cBM-MSCs seeded β-TCP scaffold transplant is achieved as confirmed by morphological, radiographical, and biomechanical analyses ([@bib97]). Another success application has been shown in canine orbital wall defect model. In this study, a combination of autologous cBM-MSCs and canine bone marrow (cBM) aspirate is seeded onto β-TCP scaffolds. After 24 weeks, a successful bone repair of orbital wall bone defects is observed compared with β-TCP scaffold and blank control ([@bib94]).

Despite the evidences supporting bone regenerative potential of cBM-MSCs, some reports have suggested the burdens in cBM-MSCs application especially the invasive harvesting protocol and the difficulty of cell expansion *in vitro* ([@bib12]; [@bib19]; [@bib60]). cBM-MSCs showed lesser *in vitro* capabilities comparing with cAD-MSCs according to initial cell isolation yield, colony forming unit (CFU) potency, and proliferation ability ([@bib12]). It has been reported that hypoxic conditions (5% and 10% oxygen tension) hampered an *in vitro* proliferation capacity of cBM-MSCs comparing with 21% oxygen tension ([@bib19]). In this regard, strategy to enhance cell isolation yield and proliferation potential of cBM-MSCs is indeed necessitated for improving the potential application of the cells for bone tissue engineering. Our report has recently suggested the beneficial effects of simvastatin in low-dose range, 0.1 and 1 nM, on cBM-MSCs proliferation and pluripotent marker expression *in vitro* ([@bib59]).

4.2. Adipose-derived mesenchymal stem cells (AD-MSCs) {#sec4.2}
-----------------------------------------------------

Canine AD-MSCs (cAD-MSCs) have been isolated and characterized ([@bib80]; [@bib88]). According to the previous publications, morphology of the early passage cAD-MSCs has been described as a homogeneous spindle-shaped phenotype. The late passage morphology (after 5 passages) has changed to a wide and flat appearance ([@bib88]). The tri-lineage differentiation capacity of cAD-MSCs (adipogenicity, chondrogenicity, and osteogenicity) has been illustrated *in vitro* ([@bib12]; [@bib80]; [@bib88]). Surface marker characteristics of cAD-MSCs analyzed by flow cytometry have been defined as CD9^+^, CD44^+^,CD90^+^, CD105^+^, MHC I^+^, CD14^-^, CD29^-^, CD34^-^, CD45^-^, STRO-1^-^, and MHC II^−^ ([@bib12]; [@bib80]). The expressions of pluripotent markers (*Nanog homeobox; Nanog, Pou5f1/Oct4,* and *SRY-box 2; Sox2*) by cAD-MSCs have been illustrated using conventional PCR ([@bib12]). Canine-specific PCR array is used to identify the unique gene expression profiles of cAD-MSCs compared with canine peripheral blood mononuclear cells (cPBMCs). The results suggested that cAD-MSCs showed the similar gene expression pattern as found in cBM-MSCs. Set of upregulated genes comprised *Mmp2* and *Pdgfrβ* while set of downregulated genes included *Ptprc or Cd45, Tnf, Itgax, β2m, Il10, Pparɣ, Tgfβ1* ([@bib80]). Additionally, adipose tissues yielded lesser number of isolated cells per gram of tissue when compared with bone marrow source. However, cAD-MSCs showed greater performances comparing with cBM-MSCs in terms of CFU percentage, short- and long-term proliferation, number of population doublings, as well as cell number per culture plate ([@bib12]).

An *in vitro* osteogenic differentiation potential of cAD-MSCs has been investigated. Upon the maintenance with osteogenic induction medium containing the supplement combination as described previously in cBM-MSCs section, an *in vitro* osteogenic differentiation of cAD-MSCs is illustrated by an upregulation of osteogenic mRNA markers (*Cbfa1/Runx2, Bglap/Ocn, Col1A1, Osx,* and *BSP-1/OPN*) and the increase of alkaline phosphatase activity. The positive Alizarin Red S or *Von Kossa* staining was found in osteogenic induced cells compared to undifferentiated control suggesting the mineralization of extracellular matrix (ECM). The osteogenic differentiation potency between cAD-MSCs and cBM-MSCs is comparable especially the low responses of alkaline phosphatase activity of the both cell types upon an *in vitro* induction ([@bib12]; [@bib19]; [@bib80]; [@bib88]). rhBMP-2 supplement during osteogenic induction could enhance an *in vitro* alkaline phosphatase activity and mineralization in cAD-MSCs similar to those of cBM-MSCs ([@bib12]). Hypoxic conditions (5% and 10% oxygen tension) decreased an *in vitro* proliferation capacity and osteogenic differentiation potential of cAD-MSCs comparing with 21% oxygen tension ([@bib19]).

Potential application of cAD-MSCs in veterinary bone tissue engineering has been investigated in canine cranial bone defect model ([@bib21]). In this regard, cAD-MSCs isolated from inguinal subcutaneous fat pad are osteogenically induced and seeded on cuboid coral scaffolds (width 20 mm x height 20 mm x thickness 3 mm). After maintained for 7 days, the cells-seeded scaffolds and control scaffolds are transplanted into the bilateral critical-size parietal bone defects (20 mm × 20 mm) in each animal. Significant bone formation was observed at week 12 post-transplantation in the defects treated with cells-seeded scaffold. At 24 weeks post-transplant, the average bone formation area is 84.19 ± 6.45% and 25.04 ± 18.82% in the defects treated with cells-seeded scaffold and control scaffold, respectively. Histological analyses illustrate that the defects in cells-seeded scaffold transplant are repaired by a typical bone tissue while fibrous tissues are found in control group ([@bib21]). Recent study demonstrates the advantages of technology that could preserve the cell-to-cell interactions and the endogenous ECM connections ([@bib41]). These processes are necessary for osteogenicity and bone regenerative capability of cAD-MSCs ([@bib41]). In this study, PCL/β-TCP composite scaffolds are wrapped with osteogenically induced cAD-MSCs sheets and transplanted into the 15 mm segmental defects of canine radial diaphysis. At 12 weeks post-transplant, the new cone-shaped bone formation is observed, and the newly formed bone mass in the defects treated with cAD-MSCs sheet-wrapped scaffolds is significantly greater than that in cAD-MSCs-seeded and control scaffolds. Histological examinations revealed the newly formed bone had a woven, trabecular appearance surrounding by fibrous connective tissue with no obvious inflammation ([@bib41]). However, it should be noted that the new bone formation in this study model at 12 weeks post-transplant did not completely cover the defect.

Although cAD-MSCs possesses osteogenic differentiation and bone regeneration potential, the study regarding clinical application of cAD-MSCs for bone tissue regeneration is still limited especially in terms of bone defect model variety and effectiveness comparison between autologous and allogenic transplants.

4.3. Dental tissue-derived mesenchymal stem cells (dental-MSCs) {#sec4.3}
---------------------------------------------------------------

Isolation of various human dental-MSCs types have been previously reported e.g. human dental pulp stem cells (hDPSCs), human periodontal ligament stem cells (hPDLSCs), and stem cells from human exfoliated deciduous teeth (SHED) ([@bib25]). These dental-MSCs contained plasticity and differentiation potency toward various lineages including osteogenic, chondrogenic, adipogenic, pancreatic, and neurogenic lineages ([@bib25]; [@bib62], [@bib76], [@bib77]). In veterinary practice, canine dental pulp stem cells (cDPSCs) from canine premolars and canine periodontal ligament stem cells (cPDLSCs) have been isolated and reported ([@bib24]; [@bib89]). cDPSCs illustrate clonogenicity and contained higher proliferation rate compared with hBM-MSCs. Expression of *Nanog* mRNA, a pluripotent marker, is also observed. The expression of cell surface markers of cDPSCs were not quite correlated with those expressed in hDPSCs. Surface molecule immunophenotyping of cDPSCs using flow cytometry has been illustrated as CD90^+^ (relative low), STRO-1^+^ (relative low), CD45^-^, CD73^-^, and CD105^-^. *CD146* mRNA expression was found as analyzed by RT-qPCR ([@bib24]). In addition, previous research has shown that cPDLSCs expressed CD29^+^, CD90^+^, CD34^-^ and CD45^-^ ([@bib89]). The inconsistent surface marker expression might due to the specificity of antibodies used in flow cytometry analysis.

Osteo/odontogenic differentiation potential of cDPSCs has been investigated *in vitro*. Upon the maintenance with osteo/odontogenic induction medium containing 10 nM 1,25 dihydroxyvitamin D~3~, osteo/odontogenic differentiation of cDPSCs is illustrated by the increase of alkaline phosphatase enzymatic activity, mineral deposition, and dentin sialoprotein (DSP) expression. Neurogenic and adipogenic differentiation potential of cDPSCs is also illustrated *in vitro* ([@bib24]). There is no further analysis regarding osteo/odontogenic mRNA marker expression of cDPSCs undergone an *in vitro* induction in this study.

This evidence has preliminarily suggested the osteogenic differentiation potential of cDPSCs *in vitro*. However, according to the regenerative craniofacial/bone therapies in human, two main issues (i.e. material/scaffold technology and dental stem cell technology) have to be addressed to accomplish the veterinary clinical application using dental-MSCs-based bone tissue engineering ([@bib26]).

5. Conclusion {#sec5}
=============

Advantages and disadvantages of three canine mesenchymal stem cells are summarized in [Table 3](#tbl3){ref-type="table"}. Most of the studies regarding bone tissue engineering in various animal bone defect models were human application-aimed studies. However, there were numerous of promising studies that supported the application of MSCs for veterinary bone tissue engineering, especially cBM-MSCs. For cAD-MSCs, despite the evidences supporting osteogenic differentiation potential *in vitro*, the studies regarding an *in vivo* bone regenerative capacity and material/scaffold technology are indeed necessitated. Additionally, the promising evidences supporting the *in vitro* and *in vivo* osteogenic differentiation and bone regenerative potential of dental-MSCs are still lacking. Studies regarding these issues will fulfill the development of technologies required for the cMSC-based bone tissue engineering for veterinary practice.Table 3Advantages and disadvantages of canine mesenchymal stem cells.Table 3AdvantagesDisadvantagescBM-MSCs-Self-renewal- Multilineage differentiation potential-High yield of isolated cells-Many supporting evidences both *in vitro* and *in vivo*-Invasive harvesting procedure-*In vitro* cell expansion difficultycAD-SCs-Self-renewal-Multilineage differentiation potential-High proliferation rate-Many supporting evidences *in vitro*-Simple harvesting procedure-Multiple site collections-Morphological change (after 5 passages)-Low number of isolated cells-Less supporting evidences *in vivo*cDPSCs-Self-renewal-Multilineage differentiation potential-High proliferation rate-High osteogenic differentiation performances-Low number of isolated cells-Less evidences both *in vitro* and *in vivo*-Sample collection difficulty[^3]
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